<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02935192</url>
  </required_header>
  <id_info>
    <org_study_id>Torlak-300</org_study_id>
    <secondary_id>VAC 053</secondary_id>
    <nct_id>NCT02935192</nct_id>
  </id_info>
  <brief_title>Phase 3 Trial of Serbian Seasonal Influenza Vaccine</brief_title>
  <acronym>Torlak-300</acronym>
  <official_title>A Phase 3 Double Blinded, Randomized, Placebo- Controlled Study to Examine the Safety and Immunogenicity of a Seasonal Trivalent Split Inactivated Influenza Vaccine Produced by Institute Torlak in 18-65 Year Old Volunteers in Serbia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Virology, Vaccines and Sera, Torlak</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PATH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Comac Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institute of Virology, Vaccines and Sera, Torlak</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3, double-blind, randomized, placebo-controlled trial of a seasonal, trivalent,
      split, inactivated influenza vaccine produced by InstituteTorlak.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3, double-blind, randomized, placebo- controlled trial with two groups of
      participants to receive seasonal trivalent split, inactivated influenza vaccine (A/H1N1;
      A/H3N2 and B) or placebo (phosphate buffered saline). A total of about 480 healthy male and
      female adults 18 through 65 years of age; 320 participants will be randomized to receive
      vaccine and160 will receive placebo (a 2:1 ratio). At least 25% of the participants (N=120)
      will be &gt;/= 45 years of age (80 vaccine and 40 placebo recipients).

      Safety will be assessed in all participants through Day 91. Immunogenicity will be assessed
      in serum samples obtained at baseline and 21 days after vaccination in a subset of at least
      100 individuals randomized to study vaccine and 50 placebo recipients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 28, 2016</start_date>
  <completion_date type="Actual">March 25, 2017</completion_date>
  <primary_completion_date type="Actual">January 8, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Solicited Adverse Events (Local &amp; Systemic Reactogenicity)</measure>
    <time_frame>30-minute post-vaccination period</time_frame>
    <description>Number of participants experiencing one or more solicited local AEs, including redness /erythema, swelling / induration and pain</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Local Adverse Events (Local Reactogenicity)</measure>
    <time_frame>5-day period (Days 1-5) post-vaccination</time_frame>
    <description>Number of subjects reporting one or more solicited local reactions (redness/erythema, swelling/induration, pain, and tenderness) at the injection site post-vaccination with study vaccine or placebo</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Systemic Adverse Events (Systemic Reactogenicity)</measure>
    <time_frame>5-day period (Days 1-5) post-vaccination</time_frame>
    <description>Number of subjects reporting one or more solicited systemic reactions (fever, fatigue/malaise, muscle aches, joint aches, chills, nausea, vomiting, and headache) post-vaccination with study vaccine or placebo.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Unsolicited Adverse Events</measure>
    <time_frame>Within 21 days post vaccination</time_frame>
    <description>Unsolicited AEs occurring in 1% or more of study participants; includes events irrespective of causality</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAE)</measure>
    <time_frame>Over the entire study period (Day 91)</time_frame>
    <description>Number of participants reporting one or more of all anticipated and unanticipated serious adverse events, grouped by organ system, with number and frequency of such events in each arm/group of the clinical study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Seroconverted Subjects</measure>
    <time_frame>Day 22</time_frame>
    <description>Seroconversion is defined as a serum HAI antibody titer meeting the following criteria:
Pre-vaccination titer &lt;1:10 and a post-vaccination titer measured on Day 22 of ≥1:40; or
Pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination measured on Day 22.
Measured against each of the 3 antigens</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number and Percentage of Participants With a HAI Antibody Titer ≥1:40 (Seroprotection)</measure>
    <time_frame>Day 1 and Day 22</time_frame>
    <description>Seroprotective Titers is considered as HAI antibody Titre ≥1:40; measured for each of the 3 antigens</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Titers (GMTs) of Serum HAI Antibodies</measure>
    <time_frame>Day 1 and Day 22</time_frame>
    <description>Serum HAI Antibodies GMTs Pre- (Day 1) and Post-vaccination (Day 22); measured for each of the 3 antigens</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric Mean Fold Rises (GMFRs) of Serum HAI Antibodies</measure>
    <time_frame>Day 1 and Day 22</time_frame>
    <description>GMFR calculated as GMT for of Serum HAI Antibodies Post-vaccination/Pre-vaccination; measured for each of the 3 antigens</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">480</enrollment>
  <condition>Influenza</condition>
  <arm_group>
    <arm_group_label>Vaccine Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Seasonal trivalent split, inactivated influenza vaccine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Phosphate buffered saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccine</intervention_name>
    <description>Seasonal trivalent split, inactivated influenza vaccine 15 mcg hemagglutinin antigen (HA) of each of A/H1N1; A/H3N2 and B strains; 0.5 mL by IM injection</description>
    <arm_group_label>Vaccine Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Phosphate buffered saline, 0.5 mL by IM injection</description>
    <arm_group_label>Placebo Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 18 to 65 years on the day of screening/enrollment.

          -  Literate (by self-report) and willing to provide written informed consent.

          -  Able to attend all scheduled visits and to comply with all trial procedures.

          -  Healthy or medically stable, as established by medical history and physical
             examination. For individuals with medical conditions, symptoms/signs, if present must
             be stable under control or unchanged for the past three months. If medication is used
             to treat the condition, the medication dose must have been stable for at least one
             month preceding vaccination.

        For female participants:

          -  Not breast feeding, non-pregnant (based on negative urine pregnancy test) and no plan
             to become pregnant up to Day 22.

          -  Women who are not surgically sterile (hysterectomy or tubal ligation) or
             post-menopausal for more than one year must be willing to use effective contraceptive
             method to prevent pregnancy until three weeks (Day 22) after vaccination. Effective
             methods include intrauterine device, hormonal contraceptives (oral, injectable, patch,
             implant, ring) or double barrier contraceptives (condom or diaphragm with spermicide).
             Women with credible history of abstinence may be enrolled at the discretion of the
             investigator.

        Exclusion Criteria:

          -  Participation in another clinical trial involving any therapy within the previous
             three months or planned enrollment in such a trial during the period of this study.

          -  Receipt of influenza vaccine in the last 10 months.

          -  Receipt of any non-study vaccine within four weeks prior to enrollment or refusal to
             postpone receipt of such vaccines until after the Day 22 visit.

          -  Receipt of immune globulin or other blood products within three months prior to study
             enrollment or planned receipt of such products prior to the Day 22 visit.

          -  Known or suspected congenital or acquired immunodeficiency.

          -  Chronic administration (defined as more than 14 consecutively-prescribed days) of
             immunosuppressants or other immune-modulating therapy within six months prior to study
             enrollment. (For corticosteroids, this means prednisone or equivalent, ≥ 0.5 mg per kg
             per day; topical steroids are allowed.)

          -  Unstable illness by history or physical examination that in the opinion of the
             investigator, might interfere with the conduct or results of the study or pose
             additional risk to the participant.

          -  Hypersensitivity after previous administration of any vaccine.

          -  Suspected or known hypersensitivity to any of the study vaccine components, including
             chicken or egg protein or antibiotics.

          -  Bleeding disorder or receipt of anticoagulants in the three weeks preceding
             enrollment.

          -  Known active tuberculosis or symptoms of active tuberculosis, regardless of cause
             (self-report).

          -  Current alcohol or drug addiction that in the opinion of the Investigator, might
             interfere with the ability to comply with trial procedures.

          -  History of Guillain-Barré Syndrome.

          -  Neoplastic disease or any hematologic malignancy. Allowed: localized skin or prostate
             cancer that is no longer being treated and is stable at the time of vaccination and
             participants who have a history of neoplastic disease and who have been disease free
             for ≥ 5 years.

          -  Any condition that, in the opinion of the investigator, would increase the health risk
             to the participant if he/she participates in the study, or would interfere with the
             evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Goran Stevanovic, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Center of Serbia, Clinic for Infectious and Tropical Diseases</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Center of Serbia: Clinic for Infectious and Tropical Diseases</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Center of Serbia: Clinic for Pulmonology</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Students' Healthcare</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Health Care of Workers of the Ministry of Internal Affairs</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jevremova Special gynecology hospital with maternity</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General Hospital Vrsac</name>
      <address>
        <city>Vršac</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Serbia</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 13, 2016</study_first_submitted>
  <study_first_submitted_qc>October 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 17, 2016</study_first_posted>
  <results_first_submitted>June 18, 2018</results_first_submitted>
  <results_first_submitted_qc>January 21, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2019</results_first_posted>
  <last_update_submitted>January 21, 2019</last_update_submitted>
  <last_update_submitted_qc>January 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>seasonal influenza</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>503 subjects were consented and screened from across 6 clinical trial sites located in Belgrade and Vrsac, Serbia. Of the 503 subjects screened, 23 subjects failed screening.</recruitment_details>
      <pre_assignment_details>Twenty-three (23) subjects failed screening and were not assigned to a treatment group.
An additional 8 subjects withdrew consent prior to receiving any study product.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Vaccine Arm</title>
          <description>Trivalent seasonal influenza vaccine</description>
        </group>
        <group group_id="P2">
          <title>Placebo Arm</title>
          <description>Phosphate buffered saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="320">312 subjects were included in the Full Protocol Analysis because 8 withdrew without getting product.</participants>
                <participants group_id="P2" count="160">156 subjects were included in the Full Protocol Analysis because 4 withdrew without getting product.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Vaccine/Placebo</title>
              <participants_list>
                <participants group_id="P1" count="312"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="312"/>
                <participants group_id="P2" count="156"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants enrolled and vaccinated without major protocol deviations</population>
      <group_list>
        <group group_id="B1">
          <title>Vaccine</title>
          <description>Seasonal trivalent split, inactivated influenza vaccine
Seasonal Influenza Vaccine: Seasonal trivalent split, inactivated influenza vaccine (A/H1N1; A/H3N2 and B); 0.5 mL by IM injection</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Phosphate buffered saline
Phosphate Buffered Saline: Phosphate buffered saline, 0.5 mL by IM injection</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="312"/>
            <count group_id="B2" value="156"/>
            <count group_id="B3" value="468"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Each row represents a subpopulation of age range for the study (18-44 years; 45-65 years). Together these totals add up to the overall study population in each arm.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>18-44 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="232"/>
                    <count group_id="B2" value="116"/>
                    <count group_id="B3" value="348"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.8" lower_limit="18" upper_limit="44"/>
                    <measurement group_id="B2" value="32.0" lower_limit="18" upper_limit="44"/>
                    <measurement group_id="B3" value="32.6" lower_limit="18" upper_limit="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45-65 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="80"/>
                    <count group_id="B2" value="40"/>
                    <count group_id="B3" value="120"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.7" lower_limit="45" upper_limit="65"/>
                    <measurement group_id="B2" value="53.8" lower_limit="45" upper_limit="63"/>
                    <measurement group_id="B3" value="54.4" lower_limit="45" upper_limit="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="312"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="468"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="145"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="222"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="167"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Serbia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="312"/>
                    <count group_id="B2" value="156"/>
                    <count group_id="B3" value="468"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="312"/>
                    <measurement group_id="B2" value="156"/>
                    <measurement group_id="B3" value="468"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Adverse Events (Local &amp; Systemic Reactogenicity)</title>
        <description>Number of participants experiencing one or more solicited local AEs, including redness /erythema, swelling / induration and pain</description>
        <time_frame>30-minute post-vaccination period</time_frame>
        <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Arm</title>
            <description>Trivalent seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Adverse Events (Local &amp; Systemic Reactogenicity)</title>
          <description>Number of participants experiencing one or more solicited local AEs, including redness /erythema, swelling / induration and pain</description>
          <population>The analysis was conducted for subjects who were randomized and received a study vaccination</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hardness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature above 37 C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiredness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Local Adverse Events (Local Reactogenicity)</title>
        <description>Number of subjects reporting one or more solicited local reactions (redness/erythema, swelling/induration, pain, and tenderness) at the injection site post-vaccination with study vaccine or placebo</description>
        <time_frame>5-day period (Days 1-5) post-vaccination</time_frame>
        <population>Full analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Arm</title>
            <description>Trivalent seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Local Adverse Events (Local Reactogenicity)</title>
          <description>Number of subjects reporting one or more solicited local reactions (redness/erythema, swelling/induration, pain, and tenderness) at the injection site post-vaccination with study vaccine or placebo</description>
          <population>Full analysis population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hardness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="160"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited Systemic Adverse Events (Systemic Reactogenicity)</title>
        <description>Number of subjects reporting one or more solicited systemic reactions (fever, fatigue/malaise, muscle aches, joint aches, chills, nausea, vomiting, and headache) post-vaccination with study vaccine or placebo.</description>
        <time_frame>5-day period (Days 1-5) post-vaccination</time_frame>
        <population>Full analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Arm</title>
            <description>Trivalent seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited Systemic Adverse Events (Systemic Reactogenicity)</title>
          <description>Number of subjects reporting one or more solicited systemic reactions (fever, fatigue/malaise, muscle aches, joint aches, chills, nausea, vomiting, and headache) post-vaccination with study vaccine or placebo.</description>
          <population>Full analysis population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Chills</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint Aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle Aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nausea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Temperature</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tiredness</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Unsolicited Adverse Events</title>
        <description>Unsolicited AEs occurring in 1% or more of study participants; includes events irrespective of causality</description>
        <time_frame>Within 21 days post vaccination</time_frame>
        <population>Full analysis population</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Arm</title>
            <description>Trivalent seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Unsolicited Adverse Events</title>
          <description>Unsolicited AEs occurring in 1% or more of study participants; includes events irrespective of causality</description>
          <population>Full analysis population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Nasopharyngitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Respiratory tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rhinitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Adverse Events (SAE)</title>
        <description>Number of participants reporting one or more of all anticipated and unanticipated serious adverse events, grouped by organ system, with number and frequency of such events in each arm/group of the clinical study.</description>
        <time_frame>Over the entire study period (Day 91)</time_frame>
        <population>Full Analysis Population</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Arm</title>
            <description>Trivalent seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAE)</title>
          <description>Number of participants reporting one or more of all anticipated and unanticipated serious adverse events, grouped by organ system, with number and frequency of such events in each arm/group of the clinical study.</description>
          <population>Full Analysis Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Acute Lymphocytic Leukemia</title>
              <category_list>
                <category>
                  <title>Related</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not related</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not reporting this SAE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="311"/>
                    <measurement group_id="O2" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicocele</title>
              <category_list>
                <category>
                  <title>Related</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not related</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not reporting this SAE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="311"/>
                    <measurement group_id="O2" value="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Seroconverted Subjects</title>
        <description>Seroconversion is defined as a serum HAI antibody titer meeting the following criteria:
Pre-vaccination titer &lt;1:10 and a post-vaccination titer measured on Day 22 of ≥1:40; or
Pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination measured on Day 22.
Measured against each of the 3 antigens</description>
        <time_frame>Day 22</time_frame>
        <population>Per Protocol (PP) Population:
Immunogenicity was assessed in a subset of 151 participants (per-protocol population) with valid post-vaccination immunogenicity measures and no major protocol violations that were determined to potentially interfere with the immunogenicity assessment of the study vaccine. This was decided before unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Arm</title>
            <description>Trivalent seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Seroconverted Subjects</title>
          <description>Seroconversion is defined as a serum HAI antibody titer meeting the following criteria:
Pre-vaccination titer &lt;1:10 and a post-vaccination titer measured on Day 22 of ≥1:40; or
Pre-vaccination titer ≥1:10 and at least a four-fold increase in post-vaccination measured on Day 22.
Measured against each of the 3 antigens</description>
          <population>Per Protocol (PP) Population:
Immunogenicity was assessed in a subset of 151 participants (per-protocol population) with valid post-vaccination immunogenicity measures and no major protocol violations that were determined to potentially interfere with the immunogenicity assessment of the study vaccine. This was decided before unblinding.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroconversion to H1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion to H3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion to B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number and Percentage of Participants With a HAI Antibody Titer ≥1:40 (Seroprotection)</title>
        <description>Seroprotective Titers is considered as HAI antibody Titre ≥1:40; measured for each of the 3 antigens</description>
        <time_frame>Day 1 and Day 22</time_frame>
        <population>Per Protocol (PP) Population:
Immunogenicity was assessed in a subset of 151 participants (per-protocol population) with valid post-vaccination immunogenicity measures and no major protocol violations that were determined to potentially interfere with the immunogenicity assessment of the study vaccine. This was decided before unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Arm</title>
            <description>Trivalent seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Number and Percentage of Participants With a HAI Antibody Titer ≥1:40 (Seroprotection)</title>
          <description>Seroprotective Titers is considered as HAI antibody Titre ≥1:40; measured for each of the 3 antigens</description>
          <population>Per Protocol (PP) Population:
Immunogenicity was assessed in a subset of 151 participants (per-protocol population) with valid post-vaccination immunogenicity measures and no major protocol violations that were determined to potentially interfere with the immunogenicity assessment of the study vaccine. This was decided before unblinding.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seroprotection to H1N1 : Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroprotection to H1N1 : Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion to H3N2 : Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroconversion to H3N2 : Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroprotection to B : Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seroprotection to B : Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Titers (GMTs) of Serum HAI Antibodies</title>
        <description>Serum HAI Antibodies GMTs Pre- (Day 1) and Post-vaccination (Day 22); measured for each of the 3 antigens</description>
        <time_frame>Day 1 and Day 22</time_frame>
        <population>Per Protocol (PP) Population:
Immunogenicity was assessed in a subset of 151 participants (per-protocol population) with valid post-vaccination immunogenicity measures and no major protocol violations that were determined to potentially interfere with the immunogenicity assessment of the study vaccine. This was decided before unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Arm</title>
            <description>Trivalent seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titers (GMTs) of Serum HAI Antibodies</title>
          <description>Serum HAI Antibodies GMTs Pre- (Day 1) and Post-vaccination (Day 22); measured for each of the 3 antigens</description>
          <population>Per Protocol (PP) Population:
Immunogenicity was assessed in a subset of 151 participants (per-protocol population) with valid post-vaccination immunogenicity measures and no major protocol violations that were determined to potentially interfere with the immunogenicity assessment of the study vaccine. This was decided before unblinding.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMT to H1 : Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="12.3" upper_limit="18.1"/>
                    <measurement group_id="O2" value="24.1" lower_limit="16.9" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to H1 Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="336.3" lower_limit="268.2" upper_limit="421.7"/>
                    <measurement group_id="O2" value="25.0" lower_limit="17.7" upper_limit="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to H3 : Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="6.0" upper_limit="7.8"/>
                    <measurement group_id="O2" value="8.0" lower_limit="6.4" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to H3 : Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.4" lower_limit="65.9" upper_limit="118.5"/>
                    <measurement group_id="O2" value="8.4" lower_limit="6.6" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to B : Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" lower_limit="21.6" upper_limit="34.8"/>
                    <measurement group_id="O2" value="21.9" lower_limit="15.8" upper_limit="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMT to B : Day 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="103.5" lower_limit="86.9" upper_limit="123.3"/>
                    <measurement group_id="O2" value="36.1" lower_limit="26.7" upper_limit="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Geometric Mean Fold Rises (GMFRs) of Serum HAI Antibodies</title>
        <description>GMFR calculated as GMT for of Serum HAI Antibodies Post-vaccination/Pre-vaccination; measured for each of the 3 antigens</description>
        <time_frame>Day 1 and Day 22</time_frame>
        <population>Per Protocol (PP) Population:
Immunogenicity was assessed in a subset of 151 participants (per-protocol population) with valid post-vaccination immunogenicity measures and no major protocol violations that were determined to potentially interfere with the immunogenicity assessment of the study vaccine. This was decided before unblinding.</population>
        <group_list>
          <group group_id="O1">
            <title>Vaccine Arm</title>
            <description>Trivalent seasonal influenza vaccine</description>
          </group>
          <group group_id="O2">
            <title>Placebo Arm</title>
            <description>Phosphate buffered saline</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rises (GMFRs) of Serum HAI Antibodies</title>
          <description>GMFR calculated as GMT for of Serum HAI Antibodies Post-vaccination/Pre-vaccination; measured for each of the 3 antigens</description>
          <population>Per Protocol (PP) Population:
Immunogenicity was assessed in a subset of 151 participants (per-protocol population) with valid post-vaccination immunogenicity measures and no major protocol violations that were determined to potentially interfere with the immunogenicity assessment of the study vaccine. This was decided before unblinding.</population>
          <units>Titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GMFR for H1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="17.5" upper_limit="28.9"/>
                    <measurement group_id="O2" value="1.0" lower_limit="0.9" upper_limit="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR for H3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="9.8" upper_limit="17.0"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1.0" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GMFR for B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="3.0" upper_limit="4.8"/>
                    <measurement group_id="O2" value="1.6" lower_limit="1.3" upper_limit="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>90 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vaccine</title>
          <description>Trivalent seasonal influenza vaccine</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Phosphate buffered saline</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute Lymphocytic Leukemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="312"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="312"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="312"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="156"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="312"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="156"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No limitations</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Katarina Ilic</name_or_title>
      <organization>Institute of Virology, Vaccines and Sera, Torlak</organization>
      <phone>+381 11 3953 700 ext 214</phone>
      <email>kilic@torlak.rs</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

